INT51530

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 1994
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 11
Total Number 12
Disease Relevance 3.83
Pain Relevance 9.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Adk) nucleus (Adk) kinase activity (Adk)
Anatomy Link Frequency
spinal 1
Adk (Mus musculus)
Pain Link Frequency Relevance Heat
adenocard 160 100.00 Very High Very High Very High
Analgesic 16 100.00 Very High Very High Very High
antinociception 17 99.12 Very High Very High Very High
Bioavailability 4 98.92 Very High Very High Very High
MU agonist 2 98.72 Very High Very High Very High
intrathecal 6 97.74 Very High Very High Very High
Pain 12 97.48 Very High Very High Very High
Antinociceptive 36 97.40 Very High Very High Very High
Neurotransmitter 14 97.28 Very High Very High Very High
narcan 6 97.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Epilepsy 29 99.40 Very High Very High Very High
Nociception 31 98.40 Very High Very High Very High
Pain 12 97.48 Very High Very High Very High
Injury 7 97.44 Very High Very High Very High
INFLAMMATION 17 97.08 Very High Very High Very High
Convulsion 11 96.96 Very High Very High Very High
Myeloid Leukemia 86 88.08 High High
Toxicity 15 77.60 Quite High
Cancer 9 70.52 Quite High
Apoptosis 2 69.60 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Endogenous purinergic systems mediating antinociception, and their interactions with opioids, were characterized following intrathecal (i.t.) administration of inhibitors of adenosine clearance in mice. 5'-Amino,5'-deoxyadenosine (5'-NH2dAdo), an inhibitor of adenosine kinase, induced significant antinociception after i.t. injection and enhanced antinociception induced by selected opioids (i.t.).
Negative_regulation (inhibitor) of adenosine kinase associated with antinociception, adenocard, opioid and intrathecal
1) Confidence 0.56 Published 1994 Journal Eur. J. Pharmacol. Section Abstract Doc Link 7698211 Disease Relevance 0 Pain Relevance 1.35
Adenosine kinase and adenosine deaminase inhibition modulate spinal adenosine- and opioid agonist-induced antinociception in mice.
Negative_regulation (inhibition) of Adenosine kinase in spinal associated with antinociception, mu agonist and adenocard
2) Confidence 0.56 Published 1994 Journal Eur. J. Pharmacol. Section Title Doc Link 7698211 Disease Relevance 0 Pain Relevance 1.69
Inhibition of the ADO-metabolizing enzyme, ADO kinase (AK), provides a means of locally enhancing extracellular ADO concentrations.
Negative_regulation (Inhibition) of AK associated with adenocard
3) Confidence 0.55 Published 1999 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 10340527 Disease Relevance 0.25 Pain Relevance 0.41
Inhibition of adenosine metabolism by administration of an adenosine kinase inhibitor, in the present study, decreased behavior induced by putative pain neurotransmitters providing additional support for an endogenous purinergic system.
Negative_regulation (inhibitor) of adenosine kinase associated with pain, neurotransmitter and adenocard
4) Confidence 0.43 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8891573 Disease Relevance 0.39 Pain Relevance 0.84
Inhibition of the ADO-metabolizing enzyme adenosine kinase (AK) increases extracellular ADO concentrations at sites of tissue trauma and AK inhibitors may have therapeutic potential as analgesic and anti-inflammatory agents.
Negative_regulation (Inhibition) of ADO-metabolizing enzyme adenosine kinase associated with adenocard, inflammation, analgesic and injury
5) Confidence 0.39 Published 2000 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11082453 Disease Relevance 0.36 Pain Relevance 0.74
Inhibition of the ADO-metabolizing enzyme adenosine kinase (AK) increases extracellular ADO concentrations at sites of tissue trauma and AK inhibitors may have therapeutic potential as analgesic and anti-inflammatory agents.
Negative_regulation (Inhibition) of AK associated with adenocard, inflammation, analgesic and injury
6) Confidence 0.39 Published 2000 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11082453 Disease Relevance 0.36 Pain Relevance 0.74
In the present study, the AK inhibitors 5'-amino,5'-deoxy-ADO (NH2dADO), 5-iodotubercidin (5-IT), and 5'-deoxy,5-iodotubercidin (5'd-5IT) were examined for their analgesic efficacy in the hot-plate model of acute somatic nociception.
Spec (examined) Negative_regulation (inhibitors) of AK associated with nociception, adenocard and analgesic
7) Confidence 0.35 Published 1999 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 10340527 Disease Relevance 0.26 Pain Relevance 0.41
Thus, ABT-702 is a novel and potent non-nucleoside AK inhibitor that effectively reduces acute thermal nociception in the mouse by a nonopioid, non-nonsteroidal anti-inflammatory drug, ADO A(1) receptor-mediated mechanism.
Negative_regulation (inhibitor) of AK associated with nociception, adenocard, inflammation and cinod
8) Confidence 0.25 Published 2000 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11082453 Disease Relevance 0.42 Pain Relevance 0.86
ABT-702 is a novel and potent (IC(50) = 1. 7 nM) non-nucleoside AK inhibitor that has several orders of magnitude selectivity over other sites of ADO interaction (A(1), A(2A), A(3) receptors, ADO transporter, and ADO deaminase).
Negative_regulation (inhibitor) of AK associated with adenocard
9) Confidence 0.25 Published 2000 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 11082453 Disease Relevance 0.35 Pain Relevance 0.77
In support of this, adenosine deaminase inhibitors and adenosine kinase inhibitors prolong the extracellular bioavailability of adenosine and have antinociceptive effects in animals [17,21,45,46].
Negative_regulation (inhibitors) of adenosine kinase associated with adenocard, antinociceptive and bioavailability
10) Confidence 0.06 Published 2010 Journal Mol Pain Section Body Doc Link PMC2874211 Disease Relevance 0.06 Pain Relevance 0.76
Furthermore, adenosine kinase inhibition may also promote increased levels of extracellular adenosine thereby providing antiepileptic effects [22].
Negative_regulation (inhibition) of adenosine kinase associated with adenocard
11) Confidence 0.03 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583203 Disease Relevance 0.80 Pain Relevance 0.49
However, MK-0457 has also been shown to bind to and inhibit the Abl kinase (Young et al 2006; Buser et al 2007; Cheetham et al 2007) in a mode that accommodates the substitution of the bulkier isoleucine for threonine at residue 315 (Figure 3, left panel), but the relative contributions of AK, JAK-2, and Bcr-Abl inhibition in the activity of MK-0457 have not been elucidated (Giles et al 2007b).
Negative_regulation (inhibition) of AK
12) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.56 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox